<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02388672</url>
  </required_header>
  <id_info>
    <org_study_id>GCB1</org_study_id>
    <nct_id>NCT02388672</nct_id>
  </id_info>
  <brief_title>Evaluation of Effects of Green Coffee Bean Extract (GCE) on Physiological and Psychological Variables</brief_title>
  <official_title>Evaluation of Effects of Green Coffee Bean Extract (GCE) on Physiological and Psychological Variables- a Randomized, Placebo-controlled and Double-blinded Study in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coffee as one of the most favorite worldwide beverages comprises a variety of chemicals with
      health benefits. Most investigations have so far focused on the beneficial effects of
      caffeine but knowledge about non-caffeine coffee compounds such as chlorogenic acid (CGA) is
      scarce. The reducing risk of a variety of diseases following CGA consumption has been
      mentioned in recent basic and clinical studies. However, there is a lack of studies that
      examine the behavioral effects of CGA. This study aims to fill this gap.

      In a randomized double-blind study, the investigators test the acute effects of coffee
      enriched with CGA or CGA supplement on physiological functions such as blood pressure, blood
      glucose, and heart rate, and on psychological functions such as mood and cognitive
      performance in 30 healthy adult subjects (18-40 years).

      Participants will be allocated to an intervention plan using computer-generated random
      numbers. Treatments comprise of (1) 6g decaffeinated (5 mg caffeine) coffee (250 ml) with
      high total CGA (560 mg), or (2) 6g decaffeinated coffee (250 ml) with normal total CGA (224
      mg), or (3) 6g decaffeinated coffee (250 ml) with normal total CGA and 800mg green coffee
      bean extract with total CGA (560mg), or (4) 6g decaffeinated coffee (250 ml) with normal
      total CGA and placebo, or (5) no treatment group. Upon arrival in the laboratory,
      participants will complete a 24-hour food recall, a psychometric test battery, and mood and
      cognitive performance tests. The tests will be repeated 40 min following CGA application,
      which coincide with the approximated peak of CGA blood concentrations and at 120 min post
      treatment. Blood pressure, blood glucose and heart rate recordings will be taken prior to
      treatment and at 1, 30, 60, 90 and 120 min post-treatment. The response to GCE-enriched
      coffee will be compared to GCE supplement for each of the groups of variables.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coffee as one of the most favorite worldwide beverages comprises a variety of chemicals
      maintaining the greatest health benefits among the commonly consumed beverages. Most
      investigations have so far focused on the beneficial effects of caffeine. On the contrary,
      knowledge on potential health benefits of non-caffeine coffee compounds is scarce. Coffee
      contains many polyphenols, especially chlorogenic acids (CGA), which have purported
      antioxidant abilities. With increasing incidence of degenerative diseases, the general public
      is turning to use natural herbal supplements, as one of these agents, CGA has been
      biologically and medically emphasized and can be expected to become a topic addressed in
      future studies, medical trends and pharmacology. The reducing risk of a variety of diseases
      following CGA consumption has been mentioned in recent basic and clinical studies. However,
      there is a lack of studies that examine the behavioral effects of CGA. This study aims to
      fill this gap.

      In a randomized double-blind study, the investigators test the acute effects of coffee
      enriched with CGA or CGA supplement on physiological functions such as blood pressure, blood
      glucose, and heart rate, and on psychological functions such as mood and cognitive
      performance in 30 healthy adult subjects (18-40 years).

      Participants will be allocated to an intervention plan using computer-generated random
      numbers. Treatments comprise of (1) 6g decaffeinated (5 mg caffeine) coffee (250 ml) with
      high total CGA (560 mg), or (2) 6g decaffeinated coffee (250 ml) with normal total CGA (224
      mg) , or (3) 6g decaffeinated coffee (250 ml) with normal total CGA and 800mg green coffee
      bean extract with total CGA (560mg), or (4) 6g decaffeinated coffee (250 ml) with normal
      total CGA and placebo, or (5) no treatment group. Participants will be instructed to abstain
      from alcohol, foods, and beverages containing caffeine, chlorogenic acids and high polyphenol
      content for 24 hours prior to the experiment. Upon arrival in the laboratory, participants
      will complete a 24-hour food recall, a psychometric test battery consisting of the
      questionnaire on competence and control beliefs (FKK), the Life Orientation Test-Revised
      (LOT-R), the Beliefs about Medicines Questionnaire (BMQ), the Sensitivity to Punishment and
      Reward Questionnaire (SPSRQ), General Self-Efficacy (SWE) questionnaire, and mood and
      cognitive performance tests consisting of the Profile of Mood States (POMS) questionnaire, a
      parametric Go/no-Go test (PGNG) and the California Verbal Learning Test (CVLT). The POMS,
      Go/no-Go, and CVLT will be repeated 40 min following CGA application, which coincide with the
      approximated peak of CGA blood concentrations and at 120 min post treatment. Blood pressure,
      blood glucose and heart rate recordings will be taken prior to treatment and at 1, 30, 60, 90
      and 120 min post-treatment. The response to GCE-enriched coffee will be compared to GCE
      supplement for each of the groups of variables.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Personnel changes
  </why_stopped>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood pressure</measure>
    <time_frame>from baseline to 30 min after intake of CGA</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>from baseline to 30 min after intake of CGA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood glucose</measure>
    <time_frame>from baseline to 30 min after intake of CGA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mood (Profile of Mood States (POMS) questionnaire)</measure>
    <time_frame>from baseline to 30 min after intake of CGA</time_frame>
    <description>Assessed with the Profile of Mood States (POMS) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive performance (parametric go/no-go task)</measure>
    <time_frame>from baseline to 30 min after intake of CGA</time_frame>
    <description>Assessed with a parametric go/no-go task measuring reaction times, attention (percentage of correct trials), and inhibition (percentage of correct inhibited trials)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Drink high-CGA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will drink once 250ml of decaffeinated coffee enriched with chlorogenic acid (CGA) (6g decaffeinated coffee (5 mg caffeine) with high total CGA (560 mg)).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drink low-CGA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6g decaffeinated coffee (250 ml) with normal total CGA (224 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capsules high-CGA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6g decaffeinated coffee (250 ml) with normal total CGA and 800mg green coffee bean extract supplement with total CGA (560mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capsules low-CGA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6g decaffeinated coffee (250 ml) with normal total CGA and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>decaffeinated coffee</intervention_name>
    <description>Decaffeinated coffee with low chlorogenic acid (224mg; low-CGA)</description>
    <arm_group_label>Drink high-CGA</arm_group_label>
    <arm_group_label>Drink low-CGA</arm_group_label>
    <arm_group_label>Capsules high-CGA</arm_group_label>
    <arm_group_label>Capsules low-CGA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>chlorogenic acid</intervention_name>
    <description>Decaffeinated coffee with high chlorogenic acid (560mg; high-CGA)</description>
    <arm_group_label>Drink high-CGA</arm_group_label>
    <arm_group_label>Drink low-CGA</arm_group_label>
    <arm_group_label>Capsules high-CGA</arm_group_label>
    <arm_group_label>Capsules low-CGA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>green coffee bean extract supplement</intervention_name>
    <description>Decaffeinated coffee together with green coffee bean extract supplement (560mg; high-CGA)</description>
    <arm_group_label>Capsules high-CGA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Decaffeinated coffee with placebo capsules as control group for green coffee bean extract supplement (224mg; low-CGA)</description>
    <arm_group_label>Capsules low-CGA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults between 18 and 40 years old

          -  Normal weight (BMI &gt; 18 and &lt; 25 kg/m2)

          -  Regular coffee drinkers (1 to 2 cups/day)

          -  Both male and female

        Exclusion Criteria:

          -  BMI &lt;18 or &gt;25 kg/m2

          -  Systolic blood pressure (SBP) &lt;100 or &gt;160 mmHg

          -  Diastolic blood pressure (DBP) &lt;50 or &gt;100 mmHg

          -  History of neurological, psychiatric, cardiac, endocrine or other disorders

          -  History of substance abuse

          -  Current use of antihypertensive and psychotropic medication

          -  More than 30 g/day alcohol consumption

          -  Woman who are pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle Mack, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital TÃ¼bingen</affiliation>
  </overall_official>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2015</study_first_submitted>
  <study_first_submitted_qc>March 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Dr. Isabelle Mack</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

